Sensei Biotherapeutics presented clinical data at the ESMO Congress on July 30, 2025.
1 report, 1 independent
Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sensei Biotherapeutics presented clinical data at the ESMO Congress on July 30, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Society for Medical Oncology
Professional organisation
Nothing else this week.
Related events
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.
- NMPA granted conditional approval for a drug on August 1, 2026, coinciding with the presentation of clinical trial data at ESMO.
Coverage
Newest first; wire copies grouped- GlobeNewswireSensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc.